Skip to content
10-Q

Quarterly Report

Checkmate Pharmaceuticals, Inc.

0001193125-22-148774

← back to feed
Filed
May 12, 2022 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2022 · May 12, 2022 22.04M sh
Stock Repurchased Q1 2022 · Mar 31, 2022 $4.72M
Stock Repurchased Q1 2022 · Mar 31, 2021 $3.18M
Operating Cash Flow Q1 2022 · Mar 31, 2022 −$10.67M
Operating Cash Flow Q1 2022 · Mar 31, 2021 −$14.31M
Short Term Investments Q1 2022 · Mar 31, 2022 $20.56M
Short Term Investments Q1 2022 · Dec 31, 2021 $20.19M
Cash And Equivalents Q1 2022 · Mar 31, 2022 $39.48M
Cash And Equivalents Q1 2022 · Dec 31, 2021 $50.68M
Stockholders Equity Q1 2022 · Mar 31, 2022 $55M
Stockholders Equity Q1 2022 · Dec 31, 2021 $69.46M
Stockholders Equity Q1 2022 · Mar 31, 2021 $112.4M
Stockholders Equity restated Q1 2022 · Dec 31, 2020 −$125.2M
Current Liabilities Q1 2022 · Mar 31, 2022 $11.94M
Current Liabilities Q1 2022 · Dec 31, 2021 $9.38M
Total Liabilities Q1 2022 · Mar 31, 2022 $11.94M
Total Liabilities Q1 2022 · Dec 31, 2021 $9.38M
Current Assets Q1 2022 · Mar 31, 2022 $62.11M
Current Assets Q1 2022 · Dec 31, 2021 $73.96M
Total Assets Q1 2022 · Mar 31, 2022 $66.94M
Total Assets Q1 2022 · Dec 31, 2021 $78.84M
Sga Expense Q1 2022 · Mar 31, 2022 $4.24M
Sga Expense Q1 2022 · Mar 31, 2021 $3.8M
Rd Expense Q1 2022 · Mar 31, 2022 $11.65M
Rd Expense Q1 2022 · Mar 31, 2021 $10.38M
Net Income Q1 2022 · Mar 31, 2022 −$15.87M
Net Income Q1 2022 · Mar 31, 2021 −$14.13M
Operating Income Q1 2022 · Mar 31, 2022 −$15.89M
Operating Income Q1 2022 · Mar 31, 2021 −$14.18M